These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 16908766)

  • 1. Clinical phenotype and functional characterization of CASQ2 mutations associated with catecholaminergic polymorphic ventricular tachycardia.
    di Barletta MR; Viatchenko-Karpinski S; Nori A; Memmi M; Terentyev D; Turcato F; Valle G; Rizzi N; Napolitano C; Gyorke S; Volpe P; Priori SG
    Circulation; 2006 Sep; 114(10):1012-9. PubMed ID: 16908766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abnormal calcium signaling and sudden cardiac death associated with mutation of calsequestrin.
    Viatchenko-Karpinski S; Terentyev D; Györke I; Terentyeva R; Volpe P; Priori SG; Napolitano C; Nori A; Williams SC; Györke S
    Circ Res; 2004 Mar; 94(4):471-7. PubMed ID: 14715535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abnormal interactions of calsequestrin with the ryanodine receptor calcium release channel complex linked to exercise-induced sudden cardiac death.
    Terentyev D; Nori A; Santoro M; Viatchenko-Karpinski S; Kubalova Z; Gyorke I; Terentyeva R; Vedamoorthyrao S; Blom NA; Valle G; Napolitano C; Williams SC; Volpe P; Priori SG; Gyorke S
    Circ Res; 2006 May; 98(9):1151-8. PubMed ID: 16601229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adeno-associated virus-mediated CASQ2 delivery rescues phenotypic alterations in a patient-specific model of recessive catecholaminergic polymorphic ventricular tachycardia.
    Lodola F; Morone D; Denegri M; Bongianino R; Nakahama H; Rutigliano L; Gosetti R; Rizzo G; Vollero A; Buonocore M; Napolitano C; Condorelli G; Priori SG; Di Pasquale E
    Cell Death Dis; 2016 Oct; 7(10):e2393. PubMed ID: 27711080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Catecholaminergic polymorphic ventricular tachycardia-related mutations R33Q and L167H alter calcium sensitivity of human cardiac calsequestrin.
    Valle G; Galla D; Nori A; Priori SG; Gyorke S; de Filippis V; Volpe P
    Biochem J; 2008 Jul; 413(2):291-303. PubMed ID: 18399795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calsequestrin mutations and catecholaminergic polymorphic ventricular tachycardia.
    Faggioni M; Kryshtal DO; Knollmann BC
    Pediatr Cardiol; 2012 Aug; 33(6):959-67. PubMed ID: 22421959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calsequestrin 2 (CASQ2) mutations increase expression of calreticulin and ryanodine receptors, causing catecholaminergic polymorphic ventricular tachycardia.
    Song L; Alcalai R; Arad M; Wolf CM; Toka O; Conner DA; Berul CI; Eldar M; Seidman CE; Seidman JG
    J Clin Invest; 2007 Jul; 117(7):1814-23. PubMed ID: 17607358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of SR Ca release by luminal Ca and calsequestrin in cardiac myocytes: effects of CASQ2 mutations linked to sudden cardiac death.
    Terentyev D; Kubalova Z; Valle G; Nori A; Vedamoorthyrao S; Terentyeva R; Viatchenko-Karpinski S; Bers DM; Williams SC; Volpe P; Gyorke S
    Biophys J; 2008 Aug; 95(4):2037-48. PubMed ID: 18469084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Compound heterozygous CASQ2 mutations and long-term course of catecholaminergic polymorphic ventricular tachycardia.
    Josephs K; Patel K; Janson CM; Montagna C; McDonald TV
    Mol Genet Genomic Med; 2017 Nov; 5(6):788-794. PubMed ID: 29178653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A mutation in calsequestrin, CASQ2D307H, impairs Sarcoplasmic Reticulum Ca2+ handling and causes complex ventricular arrhythmias in mice.
    Dirksen WP; Lacombe VA; Chi M; Kalyanasundaram A; Viatchenko-Karpinski S; Terentyev D; Zhou Z; Vedamoorthyrao S; Li N; Chiamvimonvat N; Carnes CA; Franzini-Armstrong C; Györke S; Periasamy M
    Cardiovasc Res; 2007 Jul; 75(1):69-78. PubMed ID: 17449018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel heterozygous mutation in cardiac calsequestrin causes autosomal dominant catecholaminergic polymorphic ventricular tachycardia.
    Gray B; Bagnall RD; Lam L; Ingles J; Turner C; Haan E; Davis A; Yang PC; Clancy CE; Sy RW; Semsarian C
    Heart Rhythm; 2016 Aug; 13(8):1652-60. PubMed ID: 27157848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modest reductions of cardiac calsequestrin increase sarcoplasmic reticulum Ca2+ leak independent of luminal Ca2+ and trigger ventricular arrhythmias in mice.
    Chopra N; Kannankeril PJ; Yang T; Hlaing T; Holinstat I; Ettensohn K; Pfeifer K; Akin B; Jones LR; Franzini-Armstrong C; Knollmann BC
    Circ Res; 2007 Sep; 101(6):617-26. PubMed ID: 17656677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The human CASQ2 mutation K206N is associated with hyperglycosylation and altered cellular calcium handling.
    Kirchhefer U; Wehrmeister D; Postma AV; Pohlentz G; Mormann M; Kucerova D; Müller FU; Schmitz W; Schulze-Bahr E; Wilde AA; Neumann J
    J Mol Cell Cardiol; 2010 Jul; 49(1):95-105. PubMed ID: 20302875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cardiac ryanodine receptor luminal Ca2+ sensor governs Ca2+ waves, ventricular tachyarrhythmias and cardiac hypertrophy in calsequestrin-null mice.
    Zhang J; Chen B; Zhong X; Mi T; Guo A; Zhou Q; Tan Z; Wu G; Chen AW; Fill M; Song LS; Chen SR
    Biochem J; 2014 Jul; 461(1):99-106. PubMed ID: 24758151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of cytosolic and intra-sarcoplasmic reticulum calcium waves by calsequestrin in rat cardiac myocytes.
    Kubalova Z; Györke I; Terentyeva R; Viatchenko-Karpinski S; Terentyev D; Williams SC; Györke S
    J Physiol; 2004 Dec; 561(Pt 2):515-24. PubMed ID: 15486014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Probing cationic selectivity of cardiac calsequestrin and its CPVT mutants.
    Bal NC; Jena N; Sopariwala D; Balaraju T; Shaikh S; Bal C; Sharon A; Gyorke S; Periasamy M
    Biochem J; 2011 Apr; 435(2):391-9. PubMed ID: 21265816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CASQ2 variants in Chinese children with catecholaminergic polymorphic ventricular tachycardia.
    Li Q; Guo R; Gao L; Cui L; Zhao Z; Yu X; Yuan Y; Xu X
    Mol Genet Genomic Med; 2019 Nov; 7(11):e949. PubMed ID: 31482657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of ventricular arrhythmia and calcium dysregulation in a catecholaminergic polymorphic ventricular tachycardia mouse model carrying calsequestrin-2 mutation.
    Alcalai R; Wakimoto H; Arad M; Planer D; Konno T; Wang L; Seidman JG; Seidman CE; Berul CI
    J Cardiovasc Electrophysiol; 2011 Mar; 22(3):316-24. PubMed ID: 20807279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular adaptation to calsequestrin 2 (CASQ2) point mutations leading to catecholaminergic polymorphic ventricular tachycardia (CPVT): comparative analysis of R33Q and D307H mutants.
    Valle G; Arad M; Volpe P
    J Muscle Res Cell Motil; 2020 Sep; 41(2-3):251-258. PubMed ID: 32902830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calsequestrin mutation and catecholaminergic polymorphic ventricular tachycardia: a simulation study of cellular mechanism.
    Faber GM; Rudy Y
    Cardiovasc Res; 2007 Jul; 75(1):79-88. PubMed ID: 17531962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.